STOCK TITAN
  1. Home
  2. Sec-filings
  3. COYA
  4. [EFFECT] Coya Therapeutics, Inc. SEC Filing

[EFFECT] Coya Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 20, 2026 4:00 P.M.
Form: S-3
CIK: 0001835022
Company Name: Coya Therapeutics, Inc.
File Number: 333-294315

Source: View Original Filing on SEC EDGAR

Coya Therapeutics, Inc.

NASDAQ:COYA

View COYA Stock Overview →

COYA Rankings

#5072 Ranked by Market Cap
N/A Ranked by Dividends

COYA Latest News

Mar 18, 2026
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Mar 16, 2026
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Feb 10, 2026
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Jan 30, 2026
Coya Therapeutics Announces $11.1 Million Private Placement
Jan 20, 2026
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

COYA Latest SEC Filings

Mar 20, 2026
[424B3] Coya Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Mar 16, 2026
[S-3] Coya Therapeutics, Inc. Shelf Registration Statement
Mar 16, 2026
[10-K] Coya Therapeutics, Inc. Files Annual Report
Mar 16, 2026
[8-K] Coya Therapeutics, Inc. Reports Material Event
Mar 12, 2026
[SCHEDULE 13G] Coya Therapeutics, Inc. Passive Investment Disclosure (>5%)

COYA Stock Data

98.75M
19.27M
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON